Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Brolucizumab

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Novartis' Biologic Beovu ( Brolucizumab) Receives Approval in the U.S.
    Novartis' Biologic Beovu ( Brolucizumab) Receives Approval in the U.S.

    19 Dec 2022

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761125

    FDA
    19 Dec 2022
    Share Share
    Novartis Korea's AMD treatment Beovu wins expanded indication
    Novartis Korea's AMD treatment Beovu wins expanded indication

    17 Aug 2022

    // Lee Han-soo KOREABIOMED

    http://www.koreabiomed.com/news/articleView.html?idxno=14408

    Lee Han-soo KOREABIOMED
    17 Aug 2022
    Share Share
    Novartis Pharms' Biologic Beovu (brolucizumab-dbll) Receives Approval in U.S.
    Novartis Pharms' Biologic Beovu (brolucizumab-dbll) Receives Approval in U.S.

    09 Mar 2022

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761125

    FDA
    09 Mar 2022
    Share Share
    Novartis Pharms' Biologic Beovu (Brolucizumab) Receives Approval in the U.S.
    Novartis Pharms' Biologic Beovu (Brolucizumab) Receives Approval in the U.S.

    18 Feb 2022

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761125

    FDA
    18 Feb 2022
    Share Share
    Health Canada Issues Recall of Novartis Pharmaceuticals Canada's BEOVU (brolucizumab)eutica
    Health Canada Issues Recall of Novartis Pharmaceuticals Canada's BEOVU (brolucizumab)eutica

    05 Feb 2022

    // HEALTH CANADA

    https://recalls-rappels.canada.ca/en/alert-recall/beovu-brolucizumab-risk-intraocular-inflammation-retinal-vasculitis-andor-retinal

    HEALTH CANADA
    05 Feb 2022
    Share Share
    Beovu shows positive results in two-year Phase III trial
    Beovu shows positive results in two-year Phase III trial

    10 Dec 2021

    // Anna Begley EUROPEANPHARMACEUTICALREVIEW

    https://www.europeanpharmaceuticalreview.com/news/166232/beovu-shows-positive-results-in-two-year-phase-iii-trial/

    Anna Begley EUROPEANPHARMACEUTICALREVIEW
    10 Dec 2021
    Share Share